NCT03441529View on ClinicalTrials.gov

A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 9, 2018

Primary Completion Date

May 3, 2018

Study Completion Date

May 3, 2018

Conditions
Healthy
Interventions
DRUG

Lumicitabine

Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.

DRUG

Piperacillin/Tazobactam

Participants will receive three IV infusions of piperacillin/tazobactam combination product (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03441529 - A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants | Biotech Hunter | Biotech Hunter